Seeking Alpha
View as an RSS Feed

Vanmaarsum  

View Vanmaarsum's Comments BY TICKER:
Latest  |  Highest rated
  • Opexa Therapeutics: An Optimal Buyout Candidate Pending Successful Topline Results From Abili-T [View article]
    Nice one!
    Apr 30, 2014. 09:25 AM | Likes Like |Link to Comment
  • Will Opexa Become A Multi-Bagger? [View article]
    By Bloomberg Data
    Mar. 24 (Bloomberg) -- Opexa Therapeutics Inc (OPXA US) was rated new
    "Market Outperform" at Brinson Patrick by equity analyst Christopher James. The
    12-month target price is $6.00 per share.
    Mar 25, 2014. 05:34 AM | Likes Like |Link to Comment
  • Will Opexa Become A Multi-Bagger? [View article]
    The Q4 earnings were basically a non event. Enrollment will be complete in Q2. So far no additional news.
    Mar 2, 2014. 01:52 PM | Likes Like |Link to Comment
  • Will Opexa Become A Multi-Bagger? [View article]
    " Opexa will report financial results for the year ended December 31, 2013, at the close of trading on Thursday, February 27, 2014. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 4:30 P.M. EST on Thursday, February 27"

    I Expect they will announce that enrollment has completed.
    Feb 27, 2014. 08:25 AM | Likes Like |Link to Comment
  • Will Opexa Become A Multi-Bagger? [View article]
    Thank you Georgekmarshall!
    Feb 23, 2014. 02:25 PM | Likes Like |Link to Comment
  • Will Opexa Become A Multi-Bagger? [View article]
    Thank you Marketman!
    Feb 23, 2014. 02:24 PM | Likes Like |Link to Comment
  • ImmunoCellular's ICT-107 Phase II: Patience Will Pay Off [View article]
    Management is conservative and is under promising and over delivering. I would be worried if they would bank on accelerated approval instead of preparing fo ra Phase III registration phase.
    Dec 11, 2013. 02:28 PM | 1 Like Like |Link to Comment
  • ImmunoCellular's ICT-107 Phase II: Patience Will Pay Off [View article]
    A median overall survival of over 30 months would be excellent because the will fill for accelerated approval if there is a greater than 9-month median survival increase.

    "If the results are as good as the phase 1 trial, where we saw a very robust response, and if there is a greater than 9-month median survival increase, there will be a lot of interest in talking with the FDA about accelerated approval," Dr. Black said. "But if it is an intermediate increase, such as 3 to 4 months, we will be looking at a larger phase 3 trial."

    Novel Vaccine Dramatically Boosts Survival in Glioblastoma
    Roxanne Nelson
    December 05, 2013
    http://bit.ly/18o8Rxs
    Dec 11, 2013. 12:35 PM | Likes Like |Link to Comment
  • ImmunoCellular's ICT-107 Phase II: Patience Will Pay Off [View article]
    If the complete trial group (n=124) survived by HOS GBM numbers we would have had 64th events in May 2013. By coincidence we had the 32th event, which triggerd the DMC analysis in May 2013. If there where twice as much deaths in de treatment group as in the control group the DMC would have stopped the trial, but they didn't. Ergo ICT-107 works, the question remains do we have the 9-month + median survival increase to go for accelerated approval or is it between 3 to 9 months. Time will tell....
    Dec 11, 2013. 09:06 AM | 2 Likes Like |Link to Comment
  • ImmunoCellular's ICT-107 Phase II: Patience Will Pay Off [View article]
    Nice artictle!
    Dilution is not a big risk in the short term becasue they have an ATM in place.
    Dec 11, 2013. 09:03 AM | Likes Like |Link to Comment
  • An In-Depth Look At 3 Companies Fighting GBM Brain Cancer [View article]
    I would suggest a visit to the IMUC website for an update of your ICT-107 knowledge. The trial is event driven and they are awaiting the 64th event: " We anticipate that 64 events could be reached in the third or fourth quarter of 2013."
    Dec 9, 2013. 10:20 AM | 1 Like Like |Link to Comment
  • How Do You Fake 7 Of 16 Five-Year Glioblastoma Survivors? [View article]
    "(..)there will be a lot of interest in talking with the FDA about accelerated approval,"

    http://bit.ly/18o8Rxs
    Dec 6, 2013. 05:57 AM | 1 Like Like |Link to Comment
  • How Do You Fake 7 Of 16 Five-Year Glioblastoma Survivors? [View article]
    Novel Vaccine Dramatically Boosts Survival in Glioblastoma

    Roxanne Nelson
    December 05, 2013

    "If the results are as good as the phase 1 trial, where we saw a very robust response, and if there is a greater than 9-month median survival increase, there will be a lot of interest in talking with the FDA about accelerated approval," Dr. Black said. "But if it is an intermediate increase, such as 3 to 4 months, we will be looking at a larger phase 3 trial."
    Dec 6, 2013. 05:49 AM | 2 Likes Like |Link to Comment
  • If Northwest Biotherapeutics Wins, It Wins Big [View article]
    Grant your numbers in Table 2 are not up to date:
    For IMUC medion OS in Phase I is: 38.4 months.

    http://bit.ly/18Z99ux

    Furthermore there are some issues with the Phase II trial NWBo is conducting, still not fully enrolled, no control group etc.
    Dec 2, 2013. 06:40 AM | 7 Likes Like |Link to Comment
  • How Do You Fake 7 Of 16 Five-Year Glioblastoma Survivors? [View article]
    MAXIM:
    "09:48 IMUC
    ImmunoCellular Therapeutics: Does the Phase I trial data portend good results? - Maxim (2.74 +0.16)
    Maxim notes IMUC reported that eight of the 16 patients who participated in the original phase I study of ICT-107 have survived more than five years post diagnosis. Seven of the 16 participants are still living, with length of survival ranging from 60.7 to 82.7 months after diagnosis. Six of the patients also were "progression free" for more than five years, meaning the tumors did not return or require more treatment during that time. As part of its diligence, firm visited Cedars and met with trial investigators, radiologists, surgeons, and pathologists. Firm concluded that "cherry picking" GBM patients in this trial was essentially impossible. So, do these results portent good phase II data? Firm is hopeful that they do, and it sees a positive skew for a favorable data outcome."
    Nov 25, 2013. 11:21 AM | Likes Like |Link to Comment
COMMENTS STATS
44 Comments
39 Likes